Study of mirvetuximab soravtansine for FRα+ platinum-resistant ovarian cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a drug called mirvetuximab soravtansine for people with platinum-resistant ovarian cancer that has a specific protein (FRα). It's real-world research to see how well the drug works and how it affects people's daily lives.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of ovarian, fallopian tube, or peritoneal cancer called high-grade serous.
- Your cancer is platinum-resistant, meaning it stopped responding to platinum chemotherapy.
- You've had 1 to 3 prior chemotherapy treatments for your cancer.
- Your tumor tests positive for a protein called FRα in at least 75% of cells.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called mirvetuximab soravtansine (MIRV) for people with ovarian cancer that has a specific protein (FRα). It aims to see how well the drug works in real-world settings, either alone or with other treatments.
This trial tests a drug called mirvetuximab soravtansine for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer that has high levels of a protein called folate receptor-alpha (FRα). It is given through a vein (IV) and aims to stop cancer from growing.
This trial tests multiple combinations of the drug mirvetuximab soravtansine with other treatments for people with ovarian cancer. It aims to see how well these combos work and what side effects they cause.
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
This study tests a combination of two targeted drugs (mirvetuximab soravtansine and suvemcitug) for people with ovarian cancer that has come back after platinum-based chemotherapy and is no longer responding to it. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This Phase 2 trial tests a combination of two medicines (mirvetuximab soravtansine and olaparib) as ongoing “maintenance” treatment after your best response to prior platinum chemotherapy. It may help keep cancer from growing longer in certain women whose tumors strongly match a specific marker (FRalpha).
Hear when a new Folate Receptor-Alpha Positive Platinum-Resistant High-Grade Serous Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.